Praxis Precision Medicines to Participate in Upcoming Conferences
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright BioConnect Conference - Fireside chat on May 20th at 9:30am ET at NASDAQ
- Mizuho Neuro & Ophthalmology Summit - Participation on May 21st in New York City
- Jefferies Global Healthcare Conference - Corporate overview presentation on June 4th at 8:10am ET at Marriott Marquis, NYC
The company will be available for one-on-one meetings during all events, with webcasts available for select presentations through the company's website for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a tre prossimi eventi per investitori:
- H.C. Wainwright BioConnect Conference - Conversazione informale il 20 maggio alle 9:30 ET presso il NASDAQ
- Mizuho Neuro & Ophthalmology Summit - Partecipazione il 21 maggio a New York City
- Jefferies Global Healthcare Conference - Presentazione aziendale il 4 giugno alle 8:10 ET al Marriott Marquis di New York
L'azienda sar脿 disponibile per incontri individuali durante tutti gli eventi e alcune presentazioni saranno trasmesse in webcast sul sito web aziendale per 90 giorni.
Praxis Precision Medicines (NASDAQ: PRAX), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su participaci贸n en tres pr贸ximas conferencias para inversores:
- H.C. Wainwright BioConnect Conference - Charla informal el 20 de mayo a las 9:30 am ET en NASDAQ
- Mizuho Neuro & Ophthalmology Summit - Participaci贸n el 21 de mayo en la ciudad de Nueva York
- Jefferies Global Healthcare Conference - Presentaci贸n corporativa el 4 de junio a las 8:10 am ET en el Marriott Marquis, Nueva York
La compa帽铆a estar谩 disponible para reuniones individuales durante todos los eventos, y algunas presentaciones seleccionadas se transmitir谩n en webcast a trav茅s del sitio web de la empresa durante 90 d铆as.
Praxis Precision Medicines (NASDAQ: PRAX)電� 欷戩稊鞁犼步瓿� 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雼り皜鞓る姅 靹� 臧�歆� 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟:
- H.C. Wainwright BioConnect Conference - 5鞗� 20鞚� 鞓れ爠 9鞁� 30攵�(霃欕秬鞁滉皠), NASDAQ鞐愳劀 歆勴枆霅橂姅 韺岇澊鞏挫偓鞚措摐 毂勴寘
- Mizuho Neuro & Ophthalmology Summit - 5鞗� 21鞚� 雺挫殨鞁滌棎靹� 彀胳棳
- Jefferies Global Healthcare Conference - 6鞗� 4鞚� 鞓れ爠 8鞁� 10攵�(霃欕秬鞁滉皠), 雺挫殨 毵るΜ鞏错姼 毵堩�挫姢鞐愳劀 旮办梾 臧滌殧 氚滍憸
須岇偓電� 氇摖 頄夓偓 旮瓣皠 霃欖晥 1:1 氙疙寘鞚� 臧�電ロ晿氅�, 鞚茧秬 氚滍憸電� 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 90鞚缄皠 鞗轨簮鞀ろ姼搿� 鞝滉车霅╇媹雼�.
Praxis Precision Medicines (NASDAQ : PRAX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies pour les troubles du syst猫me nerveux central, a annonc茅 sa participation 脿 trois prochaines conf茅rences pour investisseurs :
- H.C. Wainwright BioConnect Conference - Discussion informelle le 20 mai 脿 9h30 ET au NASDAQ
- Mizuho Neuro & Ophthalmology Summit - Participation le 21 mai 脿 New York
- Jefferies Global Healthcare Conference - Pr茅sentation d鈥檈ntreprise le 4 juin 脿 8h10 ET au Marriott Marquis, NYC
La soci茅t茅 sera disponible pour des r茅unions individuelles lors de tous les 茅v茅nements, avec des webcasts disponibles pour certaines pr茅sentations via le site web de la soci茅t茅 pendant 90 jours.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien f眉r Erkrankungen des zentralen Nervensystems spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen angek眉ndigt:
- H.C. Wainwright BioConnect Conference 鈥� Fireside-Chat am 20. Mai um 9:30 Uhr ET am NASDAQ
- Mizuho Neuro & Ophthalmology Summit 鈥� Teilnahme am 21. Mai in New York City
- Jefferies Global Healthcare Conference 鈥� Unternehmenspr盲sentation am 4. Juni um 8:10 Uhr ET im Marriott Marquis, NYC
Das Unternehmen steht w盲hrend aller Veranstaltungen f眉r Einzelgespr盲che zur Verf眉gung, und ausgew盲hlte Pr盲sentationen werden f眉r 90 Tage 眉ber die Unternehmenswebsite als Webcast abrufbar sein.
- None.
- None.
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in three upcoming investor conferences:
- Praxis management will be participating in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference, taking place at NASDAQ on Tuesday, May 20th, at 9:30am ET. A webcast of the fireside chat will be available through this link.
- Praxis management will also be participating in the Mizuho Neuro & Ophthalmology Summit, taking place in New York City on Wednesday, May 21st.
- Praxis management will also be presenting a corporate overview at the Jefferies Global Healthcare Conference, taking place at the Marriott Marquis in New York City on Wednesday, June 4th, at 8:10am ET. A live webcast of the presentation will be available through this .
The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
Replays of the webcasted events will also be available through the 鈥溾�� page under the 鈥溾�� section of the company鈥檚 website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽and follow us on聽,听,听补苍诲听.
Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
What investor conferences is PRAX participating in during May-June 2025?
When and where is Praxis Precision Medicines presenting at the Jefferies Global Healthcare Conference?
How can investors access PRAX's conference presentations?
How can investors schedule one-on-one meetings with PRAX management at these conferences?
